Episode 663 • • 20:27 - 24:59
663: Pupil Progression Plan
GlaxoSmithKline Ebola Vaccine Fast-Tracking
GlaxoSmithKline CEO Sir Andrew Witty discusses the unprecedented pace of developing an Ebola vaccine, aiming for doses to be available by Christmas 2014. Witty emphasizes the need for government indemnification because the vaccine will be used in emergency situations before traditional long-term trials are completed. The hosts express skepticism regarding the sudden "cracking" of the vaccine code and the financial motivations involved.